See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review claims
Explore by Goal
"In the fields of observation chance favors only the prepared mind."
- Louis Pasteur
Quick Explanation
Copied
Tony Brooks’ publication record (at least from the disambiguated ORCID noted in the supplied OpenAlex extract) includes high-citation work in immuno-oncology (e.g., low-affinity CD19 CAR T persistence) and in cancer genomics / mechanism (e.g., replicative polymerase usage profiling) . However, the extract does not provide full-text methods, results, or reproducibility evidence for most papers, so a rigorous scientific-strength judgment is necessarily constrained by missing primary-study detail."
Long Explanation
Author Review (Critical, Science-Only): Tony Brooks
Date context: April 13, 2026. Evidence scope: only what is explicitly present in the user-supplied extract (bibliographic links + one provided systematic-review dataset). Where primary-study details are missing, confidence is reduced.
Evidence Inventory (from supplied extract)
Immunology / cancer therapy (CAR T): Nature Medicine article on low-affinity CD19 CAR T expansion/persistence in pediatric ALL
Genetics / replication biology: Nature Structural & Molecular Biology article on global profiling of replicative polymerase usage
Neuro-oncology genomics: Acta Neuropathologica article on molecular characterization of epilepsy-associated glioneuronal tumours
Clinical sequencing methods: Journal of Molecular Diagnostics article on accurate sample assignment in an ultrasensitive multiplex high-throughput sequencing assay for minimal residual disease
Oncogenic function / AAA+ ATPase mechanism: Leukemia article on RUVBL2 essentiality for oncogenic c-MYB function in AML
Genomic mosaicism in development: PLoS ONE case report on pathogenic mosaic TP53 mutation detected by next generation sequencing
The user-supplied raw dataset corresponds to a systematic review of critical-care trial reporting of informed consent/capacity/surrogate decision-making/IRB oversight. I treat this as independent evidence about methodological/epistemic rigor in the presented extract.
Methodological Strength (from the provided systematic-review dataset)
The systematic review (US critical-care trials, 2000–2004) reported that informed consent was mentioned in 44/51 studies and IRB approval was reported in 46/51; capacity assessment and standardized surrogate-designee terminology showed inconsistencies .
Strengths: the extract specifies a systematic-review process with multiple physicians reviewing, data extraction with consensus, descriptive statistics, and Fisher’s exact tests with Bonferroni correction for group comparisons .
Blind spots / limitations (explicit in dataset): US-only sample, reliance on primary-study reporting quality (capacity often described indirectly), and time-bound scope (2000–2004) limit generalizability .
Scientific Strength Assessment (what can/can’t be concluded from the provided extract)
What is supported: The supplied extract links Tony Brooks to peer-reviewed biomedical research spanning (i) immunotherapy in pediatric ALL (CAR T persistence) , (ii) replication-associated genomics / polymerase usage profiling , and (iii) multiple translational/clinical-genomics directions including minimal residual disease assay methodology .
What is NOT supported (with current evidence): The extract does not provide enough primary-study detail to verify key scientific-quality dimensions (e.g., effect sizes, controls, blinding/randomization in clinical studies, assay validation statistics for diagnostic pipelines, preregistration, or independent replication). Therefore, any strong claims about rigor (or lack thereof) across the majority of papers would be speculative.
Critical skepticism about bibliometrics: citation counts and journal names can reflect many confounders (field size, topicality, collaboration networks) and do not themselves demonstrate experimental validity. Here, bibliographic/journal associations are treated as weak-to-moderate evidence of impact .
Bias/error-correction awareness: because this evaluation is driven by an incomplete extract (missing full text for most papers), it is vulnerable to bias by omission and inability to check reproducibility/analysis pipelines. The systematic-review dataset partially mitigates this because it includes explicit quantitative summaries and stated limitations .
Disambiguation / attribution caution
The supplied OpenAlex snippet contains multiple “Tony/T Brooks” identities. I can only safely treat the links where an ORCID is explicitly provided in the extract as confidently attributable to that specific individual (but the extract itself is not a full author-curation record). For a rigorous author-review, the next step is to verify ORCID-to-publication mapping across all works and then inspect full-text methods/results.
Feedback:
Updated: April 13, 2026
BGPT Author Review
Scientific Quality
50%
Based only on the provided extract, I can verify that the author is associated with multiple peer-reviewed biomedical papers across immunotherapy, replication biology/genomics, and clinical sequencing/MRD assay methodology. However, the extract does not include the primary study methods/results needed to evaluate experimental rigor (controls, validation, blinding/randomization, robustness checks, and reproducibility). Therefore the scientific-quality rating is moderate and constrained by missing evidence.
Communication Quality
50%
The supplied extract contains no excerpts of the author’s writing or argumentation, so communication quality cannot be judged directly. The only evaluable content is bibliographic metadata and one provided systematic-review dataset, which does not show the author’s narrative clarity.
Author Novelty
40%
The extract suggests involvement in a range of established research directions. Without full-text framing and novelty claims, novelty cannot be assessed rigorously; thus the score is conservative.
Scientific Rigor
40%
For most papers listed, the extract lacks methodological detail needed to score rigor. One provided systematic-review dataset includes some methodological information (independent reviewers and statistical testing with Bonferroni correction), but that alone is insufficient to infer rigor across the author’s broader portfolio.
None—this request is a scientific author review, not a bioinformatics workflow, and the provided dataset is a descriptive ethics-reporting summary rather than sequence/omics data .
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“CAR T persistence improvements are explained solely by CD19 affinity reduction.” This is unlikely to be exclusively true because therapeutic persistence is influenced by multiple biological and engineering variables (manufacturing, exhaustion dynamics, trafficking), and the extract provides no mechanistic dissection .
“Replicative polymerase usage profiling is constant across cell types.” This is unlikely because polymerase usage would be expected to depend on replication program/context; the extract does not claim invariance, so the hypothesis is not supported .
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Analysis 
Hypothesis Graveyard
Discussion